The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment
Pediatric acute lymphoblastic leukemia (ALL) affects a substantial number of children every year and requires a long and rigorous course of chemotherapy treatments in three stages, with the longest phase, the maintenance phase, lasting 2–3 years. While the primary drugs used in the maintenance phase...
Main Authors: | Shoshana Rudin, Marcus Marable, R. Stephanie Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Oxford University Press
2017-04-01
|
Series: | Genomics, Proteomics & Bioinformatics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1672022917300475 |
Similar Items
-
Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol
by: Linea Natalie Toksvang, et al.
Published: (2022-05-01) -
Erythrocyte-incorporated 6-mercaptopurine metabolite levels are not affected by recent drug administration during maintenance therapy for childhood acute lymphoblastic leukemia
by: Lauryna Aukstikalne, et al.
Published: (2023-12-01) -
Model-Based Simulation of Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia
by: Felix Jost, et al.
Published: (2020-03-01) -
NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy
by: Pai AA, et al.
Published: (2021-10-01) -
Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia
by: Eun Mi Cho, et al.
Published: (2018-12-01)